Longeveron Inc. (LGVN)
NASDAQ: LGVN · Real-Time Price · USD
0.6060
+0.0038 (0.63%)
Jul 21, 2026, 4:00 PM EDT - Market closed
Longeveron Revenue
Longeveron had revenue of $398.00K in the quarter ending March 31, 2026, with 4.46% growth. This brings the company's revenue in the last twelve months to $1.22M, down -45.35% year-over-year. In the year 2025, Longeveron had annual revenue of $1.20M, down -49.87%.
Revenue (ttm)
$1.22M
Revenue Growth
-45.35%
P/S Ratio
15.65
Revenue / Employee
$32,000
Employees
38
Market Cap
19.15M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.20M | -1.19M | -49.87% |
| Dec 31, 2024 | 2.39M | 1.68M | 237.38% |
| Dec 31, 2023 | 709.00K | -513.00K | -41.98% |
| Dec 31, 2022 | 1.22M | -84.00K | -6.43% |
| Dec 31, 2021 | 1.31M | -4.32M | -76.80% |
| Dec 31, 2020 | 5.63M | -10.47K | -0.19% |
| Dec 31, 2019 | 5.64M | 3.50M | 164.17% |
| Dec 31, 2018 | 2.13M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Lipocine | 2.00M |
| Daré Bioscience | 1.16M |
| Werewolf Therapeutics | 1.14M |
| Pluri | 1.08M |
| Allarity Therapeutics | 345.00K |
| Neuphoria Therapeutics | -13.27K |
LGVN News
- 8 days ago - Longeveron presents positive laromestrocel data in Alzheimer’s disease - TheFly
- 8 days ago - Longeveron Announces Presentation of Clinical Data at the 2026 Alzheimer's Association International Conference (AAIC) that Indicate Its Cellular Therapy Laromestrocel Reduced Neuroinflammation in Patients with Alzheimer's Disease - GlobeNewsWire
- 14 days ago - Longeveron appoints Marie Washburn CFO - TheFly
- 15 days ago - Longeveron® Appoints Marie Washburn as Chief Financial Officer - GlobeNewsWire
- 20 days ago - Longeveron Transcript: AGM 2026 - Transcripts
- 4 weeks ago - New Phase 2a Clinical Data Analysis of Stem Cell Therapy Laromestrocel in Mild Alzheimer's Disease Accepted for Poster Presentation at the 2026 Alzheimer's Association International Conference (AAIC) - GlobeNewsWire
- 6 weeks ago - Longeveron granted SME status by European Medicines Agency - TheFly
- 6 weeks ago - Longeveron Granted Small or Medium-sized Enterprise (SME) Status by the European Medicines Agency (EMA) - GlobeNewsWire